Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Behav Brain Res ; 417: 113595, 2022 01 24.
Article in English | MEDLINE | ID: mdl-34592375

ABSTRACT

It has been shown that kappa opioid receptor (KOR) antagonists, such as nor-binaltorphimine (nor-BNI), have antinociceptive effects in some pain models that affect the trigeminal system. Also, its anxiolytic-like effect has been extensively demonstrated in the literature. The present study aimed to investigate the systemic, local, and central effect of nor-BNI on trigeminal neuropathic pain using the infraorbital nerve constriction model (CCI-ION), as well as to evaluate its effect on anxiety-like behavior associated with this model. Animals received nor-BNI systemically; in the trigeminal ganglion (TG); in the subarachnoid space to target the spinal trigeminal nucleus caudalis (Sp5C) or in the central amygdala (CeA) 14 days after CCI-ION surgery. Systemic administration of nor-BNI caused a significant reduction of facial mechanical hyperalgesia and promoted an anxiolytic-like effect, which was detected in the elevated plus-maze and the light-dark transition tests. When administered in the TG or CeA, the KOR antagonist was able to reduce facial mechanical hyperalgesia induced by CCI-ION, but without changing the anxiety-like behavior. Moreover, no change was observed on nociception and anxiety-like behavior after nor-BNI injection into the Sp5C. The present study demonstrated antinociceptive and anxiolytic-like effects of nor-BNI in a model of trigeminal neuropathic pain. The antinociceptive effect seems to be dissociated from the anxiolytic-like effect, at both the sites involved and at the dose need to achieve the effect. In conclusion, the kappa opioid system may represent a promising target to be explored for the control of trigeminal pain and associated anxiety. However, further studies are necessary to better elucidate its functioning and modulatory role in chronic trigeminal pain states.


Subject(s)
Anxiety/drug therapy , Chronic Pain/complications , Hyperalgesia/drug therapy , Naltrexone/analogs & derivatives , Receptors, Opioid, kappa/antagonists & inhibitors , Trigeminal Neuralgia/complications , Animals , Central Amygdaloid Nucleus/drug effects , Disease Models, Animal , Male , Naltrexone/pharmacology , Nociception/drug effects , Rats , Rats, Sprague-Dawley
2.
Physiol Behav ; 226: 113127, 2020 11 01.
Article in English | MEDLINE | ID: mdl-32777313

ABSTRACT

There is increasing evidence that the toll-like receptor 4 (TLR4) signaling pathway contribute to development of hyperalgesia in the trigeminal system. The aim of the present study was to investigate the role of TLR4 in the trigeminal ganglion (TG) in facial hyperalgesia induced by injection of Lipopolysaccharide (LPS) or intraoral mucosal incision, which is an orofacial postoperative pain model, in male Wistar rats. The TLR4 antagonist (LPS-RS, 20 µg/10 µL) was administrated 30 min before LPS injection into the TG (10 µg/10 µL) or oral mucosa (10 µg/50 µL). In the postoperative pain model, rats were treated with LPS-RS (20 µg/10 µL) into the TG for three consecutive days after the incision. Facial heat and mechanical hyperalgesia were assessed hourly after LPS injection or intraoral incision. In addition, expression of NFκB was assessed in the TG on day 3 after intraoral incision. Our results showed that blockade of TLR4 in the TG attenuated facial heat and mechanical hyperalgesia induced by LPS or by mucosal incision, and that both conditions are associated to increase of phosphorylated NFκB in the TG. In conclusion, the present study suggests that activation of TLR4-NFκB signaling pathway in the TG contributes to the development of facial heat and mechanical hyperalgesia and may contribute to pain in inflammatory oral conditions.


Subject(s)
Hyperalgesia , Toll-Like Receptor 4 , Trigeminal Ganglion , Animals , Male , Rats , Rats, Sprague-Dawley , Rats, Wistar , Signal Transduction
3.
Cephalalgia ; 40(7): 689-700, 2020 06.
Article in English | MEDLINE | ID: mdl-31856582

ABSTRACT

OBJECTIVE: To evaluate whether intraganglionic calcitonin gene-related peptide induced differential migraine-like responses in male and female rats. METHODS: Calcitonin gene-related peptide was injected in the trigeminal ganglion of male and female rats followed by assessment of periorbital mechanical allodynia with von Frey hairs. The influence of systemic treatment with sumatriptan or intraganglionic treatment with minocycline and propentofylline was determined on the calcitonin gene-related peptide-induced mechanical allodynia in male and female rats. One additional group was exposed to an aversive light 24 h after calcitonin gene-related peptide priming, followed by evaluation of periorbital mechanical threshold, and another group was tested in the elevated-plus maze. RESULTS: Intraganglionar calcitonin gene-related peptide-induced periorbital mechanical allodynia in female (0.5 to 6 h) and male rats (0.5 to 4 h). Systemic sumatriptan briefly attenuated the mechanical allodynia, but intraganglionar minocycline or propentofylline injection was effective only in male rats. Calcitonin gene-related peptide induced photic sensitivity in female and male rats (lasting 4 h and 1 h, respectively), as well as anxiety-like behavior. CONCLUSIONS: Intraganglionar calcitonin gene-related peptide may play a major role in migraine-like responses, including periorbital mechanical allodynia, light sensitivity and anxiety like-behavior. Female rats are likely to be more susceptible to calcitonin gene-related peptide effects and a better understanding of the sexual dimorphism in calcitonin gene-related peptide signaling may help to improve migraine therapy.


Subject(s)
Calcitonin Gene-Related Peptide/metabolism , Hyperalgesia/metabolism , Migraine Disorders/metabolism , Trigeminal Ganglion/metabolism , Animals , Calcitonin Gene-Related Peptide/pharmacology , Female , Hyperalgesia/chemically induced , Male , Migraine Disorders/chemically induced , Rats , Rats, Wistar , Serotonin 5-HT1 Receptor Agonists/pharmacology , Sex Characteristics , Sumatriptan/pharmacology , Trigeminal Ganglion/drug effects
4.
J Pharm Pharmacol ; 70(8): 1059-1068, 2018 Aug.
Article in English | MEDLINE | ID: mdl-29766510

ABSTRACT

OBJECTIVES: To determine whether the drug saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor which is utilized for the treatment of Diabetes Mellitus, has neuroprotective effects in the animal model of Parkinson's disease (PD) induced by 6-hydroxydopamine (6-OHDA) in rats. METHODS: Male Wistar rats (weighing 280-300 g) received a bilateral infusion of 6-OHDA in the substantia nigra. Twenty-four hours later, they were treated with saxagliptin (1 mg/kg, p.o) once daily, for 21 days. The motor function was evaluated using the open field and rotarod (RT) tests. In addition, cognition was assessed with the novel object recognition test (ORT). After the evaluation of the behavioural tests, the animals were transcardially perfused to perform immunohistochemistry staining for tyrosine hydroxylase (TH) in the substantia nigra pars compacta (SNpc). KEY FINDINGS: Saxagliptin impaired the memory of animals in the sham group. CONCLUSIONS: Saxagliptin treatment did not exhibit neuroprotection and it did not improve the cognitive and motor deficits in the 6-OHDA model of PD. Interestingly, when saxagliptin was administered to the sham animals, a cognitive decline was observed. Therefore, this drug should be investigated as a possible treatment for PTSD.


Subject(s)
Adamantane/analogs & derivatives , Behavior, Animal/drug effects , Dipeptides/therapeutic use , Neuroprotective Agents/therapeutic use , Parkinson Disease, Secondary/drug therapy , Adamantane/administration & dosage , Adamantane/therapeutic use , Animals , Dipeptides/administration & dosage , Disease Models, Animal , Dopaminergic Neurons/drug effects , Dopaminergic Neurons/pathology , Male , Memory/drug effects , Motor Activity/drug effects , Neuroprotective Agents/administration & dosage , Oxidopamine , Parkinson Disease, Secondary/chemically induced , Parkinson Disease, Secondary/pathology , Parkinson Disease, Secondary/physiopathology , Rats, Wistar , Treatment Outcome
5.
Physiol Behav ; 191: 131-137, 2018 07 01.
Article in English | MEDLINE | ID: mdl-29678597

ABSTRACT

Trigeminal neuralgia (TN) is a painful condition characterized by excruciating facial pain, which has a serious impact on quality of life. Depression and anxiety have been commonly associated with TN, but clinical studies report that these comorbidities are frequently underdiagnosed and undertreated in TN patients. Herein it was investigated if rats submitted to the infraorbital nerve constriction (CION), a model of trigeminal neuropathic pain, would display anxiety- and depressive-like behaviors in addition to the facial sensory changes in different time points after the nerve injury. CION rats developed facial heat hyperalgesia on day 5 after the nerve injury, but at this time point the time spent and the number of entries on open arms in the elevated plus maze (EPM) and the time spent on the lit compartment of light-dark transition test (LDT) was not statistically significant between SHAM and CION groups, suggesting that 5 days after CION animals do not display anxiety-like behavior. On the other hand, around 50% of CION rats developed mechanical allodynia on day 15 postsurgery and the analysis of the time spent and the number of entries on open arms on EPM and the time spent on lit compartment of LDT revealed that only CION-allodynic animals displayed anxiety-like behavior when compared to the SHAM group. The depressive-like behavior was assessed by measuring the time of immobility on the forced swim test (FST) and sucrose preference (SP) in rats previously tested for heat (day 5) and mechanical allodynia (days 15, 30 and 45) induced by CION. The evaluation of immobility time on FST and sucrose preference consumption revealed that both CION rats did not displayed depressive- and anhedonic-like behavior at any time point evaluated. Altogether, these results demonstrate that trigeminal neuropathic pain in rats leads to the development of anxiety-, but not depressive-like behavior, suggesting that the CION model represents a methodology that allows the study of drugs targeting both pain and anxiety.


Subject(s)
Anxiety/etiology , Depression/etiology , Disease Models, Animal , Hyperalgesia/physiopathology , Trigeminal Neuralgia/complications , Analysis of Variance , Animals , Dark Adaptation/physiology , Exploratory Behavior , Food Preferences/psychology , Male , Maze Learning , Physical Stimulation/adverse effects , Rats , Rats, Wistar , Sucrose/administration & dosage , Swimming/psychology
SELECTION OF CITATIONS
SEARCH DETAIL
...